Theranostics
Q1 Journal
Open Access
Journal
Country
Australia
Pacific Region
Subject Area and Category
Medicine
└
Medicine (miscellaneous)
Q1
└
Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Q1
Publisher
SJR 2025
3.370
Q1
SJR Score
H-Index
177
Citations / Doc (2yr)
12.72
Total Docs. (latest)
405
Total Citations (3yr)
18,548
Publication type
Journals
ISSN
18387640
Coverage
2012-2025
Journal Rank
#585
Subject Categories
Medicine (miscellaneous)
Q1
Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Q1
Subject Areas
Aims & Scope
Theranostics is a multidisciplinary journal that aims to provide a forum for the exchange of clinical and scientific information for the diagnostic and therapeutic molecular and nano medicine community and allied professions.The journal publishes innovative and original research articles reflecting fields of in vitro diagnostics and prognostics, in vivo molecular imaging, molecular therapeutics, image-guided therapy, biosensor, nanobiosensor and bioelectronics, system biology and translational medicine, point-of-care and personalized medicine.A broad spectrum of biomedical research that can be applied to future theranostic applications is encouraged, along with reviews, news, and commentary to bridge the gap among the laboratory, clinic, and biotechnology industries.
Abstracting & Indexing
Directory of Open Access Journals (DOAJ)
Google Scholar
Medline
PubMed
Embase
Web of Science
Detailed Metrics
| Total Docs. (latest) | 405 |
| Total Docs. (3 years) | 1,349 |
| Total Refs. | 32,645 |
| Total Citations (3 years) | 18,548 |
| Citable Docs. (3 years) | 1,349 |
| Citations / Doc. (2 years) | 12.72 |
| Ref. / Doc. | 80.60 |
| % Female | 40.8% |
Metrics Visualization
Latest year data vs 3-year cumulative figures
Publication & Citation Trend
Loading trend data from Crossref...
Top 10 Most Cited Articles
Loading articles...
Researcher Reviews
Write a ReviewNo reviews yet for this journal.
Be the first to share your experience!
Share Your Experience
Your review will be published after moderation. Email will not be displayed publicly.